Flumet

Quick links to important sections

Flumet

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flumet

Quick Facts

Classification Therapeutic Use
Azole Antifungal Drug Systemic and mucosal fungal infections

Flumet is a medication primarily used as an antifungal agent to treat a variety of systemic and localized fungal infections. The active ingredient in Flumet is fluconazole, which belongs to a class of drugs known as triazole antifungals.

Its therapeutic action involves inhibiting the fungal cytochrome P450 enzyme 14alpha -demethylase. This enzyme is essential for the production of ergosterol, a vital component of the fungal cell membrane. By disrupting the synthesis of ergosterol, Flumet effectively impairs the integrity of the fungal cell membrane, which halts the growth and spread of the infection and ultimately leads to cell death.

Flumet is prescribed for treating several types of fungal infections, including vaginitis and oral thrush (candidiasis), as well as more serious conditions such as cryptococcal meningitis and infections of the urinary tract, lungs, and blood. It is administered orally and may also be used as a prophylactic (preventive) measure against fungal infections in patients with weakened immune systems, such as those undergoing chemotherapy or bone marrow transplantation.

Regulatory References

  1. Fluconazole Mechanism of Action NIH

What side effects are possible with Flumet?

Possible Side Effects and Safety Information

The following information is strictly based on official regulatory documents concerning the safety profile of Flumet (Intranasal Influenza Vaccine).


Adverse Reactions

Adverse reactions documented in clinical trials and post-marketing experience are categorized by frequency and system. The most common solicited adverse reactions (reported in ge 10% of recipients and at least ge 5% more than placebo) generally involve the Respiratory system and Systemic complaints. These frequently reported reactions include runny nose or nasal congestion across all age groups, fever (in children 2-6 years old), and sore throat (in adults 18-49 years old). Other commonly reported effects can include headache and muscle aches.

Serious and Significant Safety Information

Serious Adverse Reactions

  • Severe Allergic Reactions (Anaphylaxis): Appropriate medical treatment must be immediately available for the management of acute anaphylactic reactions, which can occur rarely following administration.
  • Guillain-Barré Syndrome (GBS): Caution is advised if GBS has occurred within six weeks of a previous influenza vaccination.

Population-Specific and Safety Restrictions

The vaccine is contraindicated in several circumstances:

  • A history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.
  • Children and adolescents (2 through 17 years of age) receiving aspirin or aspirin-containing therapy due to the association with Reye's syndrome following wild-type influenza infection.

Specific warnings pertain to wheezing in children younger than 5 years of age with recurrent wheezing and persons of any age with asthma. Use is also not established in immunocompromised individuals or those with certain chronic medical conditions (e.g., severe heart, lung, kidney, or metabolic disorders) that predispose them to complications from wild-type influenza.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory overdose profile for Flumet is established based on documented human exposures and pharmacological data regarding drug clearance. Overdose may present with specific psychiatric and neurological manifestations, notably severe hallucination and paranoid behavior, which are reported in cases of excessive exposure.

Severe Outcomes and Emergency Action

Overdose is classified as a severe event due to the potential for significant systemic effects, including cardiovascular toxicity. High concentrations carry the risk of QT prolongation, a precursor to Torsade de pointes, and the potential for seizures.

In the event of a suspected overdose, immediate medical attention must be sought without delay. Regulatory guidance mandates contacting emergency services immediately if severe symptoms, such as collapse or seizures, are observed.

No specific antidote is known for Flumet overdose. Management focuses entirely on reducing the excessive drug concentration and providing supportive care. Officially documented procedures include symptomatic treatment, supportive measures, and gastric lavage if deemed clinically appropriate. Furthermore, regulatory labels describe haemodialysis as a procedure, noting that a three-hour session reduces the plasma concentration by approximately 50%. Special consideration for drug clearance is required for patients with impaired renal function, as the drug’s elimination half-life is significantly prolonged in this population.

Therapeutic Uses of Flumet

What Flumet Treats: Main Uses and Benefits

Flumet is generally relevant across therapeutic domains where supportive management is needed for conditions linked to fungal pathogens. The drug is commonly used for conditions that involve noticeable physiological strain.

Core Therapeutic Contexts

The medication is applied in clinical settings that involve acute or unstable symptom patterns associated with severe, deep-seated infections, such as candidemia and Cryptococcal meningitis. It also plays a role in managing symptom clusters related to inflammatory or irritative states on mucosal surfaces, including oral thrush, esophageal candidiasis, and recurrent vaginal yeast infections.

“Flumet supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.”

It is commonly used as a preventative measure for patients who may experience heightened systemic burden due to immune vulnerability, such as those undergoing chemotherapy or transplantation. This prophylactic use assists with managing the potential for symptoms associated with acute or disruptive episodes, supporting patients during difficult periods of heightened discomfort.


Quick Fact: Context for Symptom Support

Symptom Category Therapeutic Benefit
Systemic Symptoms (e.g., persistent fever) Supports maintaining functional stability during systemic infection.
Mucosal Symptoms (e.g., itching, soreness) Contributes to easing the overall symptom load and supports general well-being.
Prophylactic Use (high-risk patients) Supports patients during difficult episodes of heightened discomfort.

Regulatory References

  1. FLUCONAZOLE tablet - DailyMed - NIH

Eligibility and Restrictions for Use

Eligibility for Flumet (Fluconazole) According to Regulatory Documents

The eligibility for using Flumet is defined by regulatory authorities based on age, pre-existing conditions, and reproductive status.

Flumet is contraindicated and must not be used by patients with a known hypersensitivity to fluconazole, any related azole compounds, or excipients. Use is also strictly prohibited with certain co-administered drugs that prolong the QTc interval and are metabolized by the CYP3A4 enzyme, such as cisapride.

Population Group Official Eligibility Status
Adults and Older Adults Generally permitted for use.
Pediatric Patients Use is established for specific infections, including neonates.
Renal Impairment Requires conditional dosage reduction for multiple-dose therapy.
Hepatic Dysfunction Use is permitted, but requires caution.
Pregnancy (High-Dose) Generally not recommended or contraindicated, except for life-threatening infections.
Breastfeeding Permitted for a single, low dose, but not recommended for repeated or high-dose use.

Eligibility is further restricted for patients with conditions predisposing to cardiac arrhythmia or certain rare hereditary metabolic disorders.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Flumet (fluconazole) is documented in regulatory sources as a potent inhibitor of the human CYP2 C9 enzyme and a moderate inhibitor of CYP3 A4 and CYP2 C19. This inhibition is the basis for many officially recorded interactions, increasing the concentration of co-administered drugs.

Formal Contraindicated Combinations

The co-administration of Flumet with certain medicines is explicitly prohibited by regulatory authorities due to the documented risk of serious or life-threatening adverse cardiac events (QT prolongation).

Classification Examples of Contraindicated Medicines
Cardiotoxicity Risk Astemizole, Cisapride, Pimozide, Quinidine, Erythromycin, Terfenadine (at 400 mg/ day)

️ Documented Exposure-Altering Interactions

Certain substances require monitoring as they alter plasma exposure of Flumet or the co-administered drug, as noted in official labels.

Interacting Substance Official Effect
Rifampicin Decreases Flumet exposure by 25%.
Hydrochlorothiazide Increases Flumet concentration by 40%.
Warfarin / Cyclosporine Flumet increases levels of these drugs.

‍️ Population-Specific Notes

The elimination of Flumet is directly related to creatinine clearance. Regulatory documents note that in patients with impaired renal function, the Flumet dose may require adjustment, which is an important consideration during co-administration.

Mechanism of Action

Fungal Sterol Biosynthesis Arrest

Flumet's mechanism begins with the highly selective inhibition of the fungal enzyme, 14 alpha-demethylase (CYP51). This molecular action fundamentally blocks the pathogen's ability to synthesize ergosterol, the primary sterol essential for maintaining the fungal cell membrane's structure and function.


Membrane Failure via Toxic Accumulation

The enzyme inhibition initiates a dual cascade: it starves the fungal cell of necessary ergosterol while simultaneously causing the buildup of toxic 14 alpha-methyl sterols. This profound structural compromise leads to the cell membrane's failure, increased permeability, and leakage of cellular contents, resulting in the physiological consequence of growth cessation (fungistasis) and cell death.


Mechanistic Constraints and Pathogen Counter-Modulation

The action of the drug's mechanism is biologically constrained by the pathogen's adaptive mechanisms, such as upregulating drug efflux pumps to physically expel Flumet from the cell. Furthermore, genetic mutations in the target enzyme (CYP51) can reduce the drug's binding affinity, allowing the fungal cell to restore or maintain its essential biosynthesis process.

Dosage and Administration Information

How to Use Flumet: Official Administration Guidelines

The usage of Flumet (fluconazole) is defined by clinical guidelines and depends on the specific condition being addressed. The medication is approved for administration via two primary routes: oral (using tablets or a reconstituted suspension) and intravenous (IV).

Administration and Dosing Patterns

The required dosage and duration are highly variable. For acute, uncomplicated infections such as vaginal candidiasis, the protocol often involves a single oral dose of 150 mg. In contrast, for systemic or more serious infections (like cryptococcal meningitis), the regimen typically initiates with a high loading dose on Day 1, which is often twice the subsequent daily maintenance dose. These maintenance doses usually fall within the 100 mg to 400 mg range and are taken once daily.

Administration Constraint Official Requirement
Timing in relation to food May be taken with or without food.
IV Infusion Rate Must not exceed 10 mL per minute (slow infusion is mandated).

Population-Specific Adjustments

Clinical protocols require specific dose modifications for certain populations. For pediatric patients, the dose is calculated based on body weight (mg/kg). Furthermore, in adults with evidence of renal impairment (Creatinine Clearance le 50 mL/min), the recommended daily dose must be reduced by 50% after the first full loading dose is given. The duration of treatment is not fixed but continues until specific clinical or laboratory endpoints are met, which may range from two weeks to several months or indefinitely for prophylactic use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flumet

Evidence for Systemic Candidiasis and Deep-Seated Infections

Studies explored Flumet’s role for severe infections like candidemia, detailing what measurements and populations were included in the research. Studies examined specific outcomes, such as total mortality and the time to fungal clearance from the bloodstream, over a defined period. The findings describe patterns observed in the studies regarding the eradication of the fungus and measured survival, especially when compared with other antifungal agents. Data described different patterns related to the specific Candida species causing the infection. Data are still emerging, and there is limited information for long-term functional and survival outcomes beyond the acute treatment phase (typically 12 weeks) across all research populations.

Evidence for Cryptococcal Meningitis (Initial and Maintenance Use)

Research explored Flumet's use in strategies for both initial and maintenance phases for conditions associated with acute or disruptive episodes. The patient groups studied were primarily HIV-infected adults. Long-term studies and Randomized Controlled Trials (RCTs) explored outcomes related to overall health and recovery, such as the rate of fungal clearance from the fluid around the brain and spinal cord (CSF) and, critically, the frequency of infection relapse during extended observation periods. Evidence is limited regarding the use of Flumet as a primary, single-agent therapy for the most severe, initial infections.

Evidence for Mucosal and Localized Fungal Infections

The research was evaluated in trials assessing short-term or episodic symptom patterns in populations with conditions characterized by fluctuating or episodic manifestations. Studies monitored patient-reported outcomes describing perceived discomfort (clinical cure) and the mycological status (fungal eradication). The findings help contextualize how patients reported their experience of symptom relief in the short term. Comparative studies report patterns related to the frequency of recurrence when comparing different treatment durations. What is still uncertain is the most effective long-term strategy to prevent recurrence in high-risk, immunocompromised patients, where the risk of relapse is high.

Frequently Asked Questions (FAQ)

Common questions about Flumet (FAQ)

Q: Does Flumet treat all types of fungal infections, or only specific types of yeast?

A: Regulatory documents state that Flumet is active against specific disease-causing microorganisms, which include certain types of Candida yeast and Cryptococcus neoformans. Official product information indicates that the medicine is generally not active against certain other species, such as Candida krusei.

Q: Does Flumet treat infections of the skin, such as athlete's foot or ringworm?

A: Official labeling states that Flumet is approved for use against tinea infections (which includes athlete's foot and ringworm) and certain infections affecting the skin and nails caused by Candida species. These uses are described in the regulatory indications for the medicine.

Q: Has Flumet been associated with any changes in liver enzyme levels?

A: Official product information reports that some individuals experience increased liver enzyme levels (such as ALT and AST) while using Flumet. These changes are often described as reversible, with enzyme levels commonly returning to baseline after the medication is discontinued.

Q: Are there any known long-term side effects reported in studies of Flumet?

A: Studies and post-marketing information indicate that long-term, high-dose use of Flumet has been associated with effects such as alopecia (hair loss) and elevated liver enzyme levels. Official safety information indicates that hair loss related to the drug is often reported as reversible upon treatment discontinuation or dose adjustment.

Q: What are the most commonly reported temporary side effects of Flumet?

A: Official safety data mentions that the most common side effects reported in clinical trials are headache, nausea, and abdominal pain. These reported effects are often temporary.

Q: Is it common to experience stomach problems, such as nausea or diarrhea, with Flumet?

A: Nausea and diarrhea are commonly reported gastrointestinal side effects in studies. Regulatory documents note that nausea is a very commonly reported effect in some patient groups.

Q: Can Flumet cause a headache or dizziness?

A: Headache is listed in official documentation as a very common side effect, reported in over 10% of patients in some studies. Dizziness is also listed as a less frequent side effect of the medicine.

Q: What information is available about the risk of serious skin reactions while using Flumet?

A: Official safety information reports rare, but serious, skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Safety documents indicate that individuals may be monitored for a skin rash. Discontinuation of the drug may be necessary in the event of a severe reaction.

Q: Can taking Flumet cause temporary or permanent hair loss?

A: Hair loss (alopecia) is a documented side effect reported in post-marketing experience with Flumet, particularly during extended or high-dose therapy. Official data reports that this effect is often noted as reversible upon discontinuation of treatment.

Q: What are the reported symptoms of an allergic reaction to Flumet?

A: Official safety information reports the possibility of severe allergic reactions, including anaphylaxis (a sudden, severe reaction). Other reported symptoms include swelling of the face or lips, hives, and difficulty breathing.

Q: What is the official guidance on alcohol consumption while taking Flumet?

A: Regulatory guidance often mentions the consideration of avoiding or limiting alcohol consumption while using Flumet. This information is generally provided because both alcohol and the medication are processed by the liver, and their combined effect may increase the burden on the organ.

Q: Can Flumet affect the effectiveness of oral contraceptive pills?

A: Official regulatory documents state that Flumet may increase the concentration of certain hormonal components found in oral contraceptives. This effect is noted, and the impact may vary depending on the specific oral contraceptive being used.

Q: Does Flumet interact with common over-the-counter pain relievers, such as ibuprofen?

A: Flumet is described as an inhibitor of the CYP2C9 enzyme, which can increase the concentration of other drugs metabolized by this pathway. Some Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are processed through this pathway. Monitoring may be considered during co-administration.

Q: Does Flumet interact with medicines for diabetes?

A: Official drug interaction information indicates that Flumet can increase the blood levels of certain anti-diabetic medications, such as sulfonylureas. This effect can increase the potential risk of hypoglycemia (low blood sugar).

Q: Do certain pre-existing conditions, like diabetes, affect the safety of Flumet?

A: Official regulatory documents advise caution for patients with underlying conditions related to the liver, kidneys, or heart. Co-administration with medications for diabetes is noted as requiring close observation due to the potential for the drug to affect blood sugar levels.

Q: How quickly does the active ingredient in Flumet start acting in the body?

A: Pharmacokinetic data in regulatory documents indicates that Flumet has a high bioavailability (over 90%) after it is taken orally. Peak concentrations of the drug in the blood are typically reached within 1 to 2 hours after an oral dose.

Q: Is there any information about Flumet causing drowsiness that would affect driving or operating machinery?

A: Official warnings note that Flumet may cause side effects such as dizziness or, rarely, seizures in some individuals. Regulatory labeling addresses the consideration of driving or operating machinery if these effects are experienced.

Q: Is there any risk of becoming dependent on Flumet?

A: The medicine is not classified as a controlled substance in regulatory documents. It does not carry an associated Drug Enforcement Agency (DEA) schedule number that indicates a risk of dependence.

Q: Does the effectiveness of Flumet change after its expiration date?

A: Official regulatory guidance mandates the disposal of unused or expired medicine following local pharmaceutical waste regulations. Regulatory documents do not provide information or guarantee the effectiveness of the drug beyond its labeled expiration date.

Q: Does Flumet have any known impact on the results of routine diagnostic blood tests?

A: Official safety data confirms that Flumet can cause changes in liver enzyme levels, which may be seen in routine blood tests. The drug also has the potential to affect other lab values, such as electrolyte levels like potassium, due to its documented effects on cardiac risk.

Q: Does Flumet interact with common herbal supplements?

A: Specific information on common herbal supplements is generally not provided in official drug interaction sections. However, because Flumet inhibits CYP enzymes, it may potentially affect the concentration of some herbal products that are metabolized by this pathway.

Q: How long does the active ingredient in Flumet usually stay in the system after the last use?

A: Regulatory documents describe the terminal elimination half-life of the active ingredient in the body. This is the time it takes for half of the drug to be eliminated, which is approximately 30 hours in healthy volunteers, though the range can vary.

How should Flumet be stored and disposed of?

How to Store and Dispose of Flumet: Official Regulatory Information

Official regulatory documents define specific storage and disposal requirements for Flumet to ensure product stability and safety. This information is based on governmental labeling.

Storage Requirement Official Guidance
Temperature Store at or below 25 C or 30 C, depending on the formulation.
Environment Protect from direct sunlight and store in a dry location.
Child Safety Mandatory instruction to keep Flumet out of the sight and reach of children.
Disposal Dispose of unused or expired medicine in accordance with local pharmaceutical waste regulations; do not flush down a toilet or pour down a drain.

All handling and storage must align with these labeled conditions, including keeping the product in its original container. Any disposal must follow established procedures for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Flumet found in:

A-Z Index: